Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sanofi’s Once-Daily Diabetes Drug Wins FDA Approval

XTALKS VITALS NEWS

Diabetes

The injection is designed to help adult patients with type 2 diabetes maintain healthy blood sugar levels.

Tweetables from this article:

Tweet: Sanofi's new #diabetes drug is now a direct competitor to Novo Nordisk's Victoza and Lilly's Trulicity http://ctt.ec/kJfR7+Sanofi's new diabetes drug is now a direct competitor to Novo Nordisk's Victoza and Lilly's Trulicity.

Tweet: Sanofi planned to submit application for #diabetes drug in 2013 but the agency asked for additional safety studies http://ctt.ec/glaB8+Sanofi planned to submit application for diabetes drug in 2013 but the agency asked for additional safety studies.

Share this!

July 29, 2016 | by Sarah Massey, M.Sc.

The US Food and Drug Administration (FDA) has approved Sanofi’s once-daily diabetes drug, Adlyxin (lixisenatide). The injection is designed to help adult patients with type 2 diabetes maintain healthy blood sugar levels.

Sanofi waited years to get approval for the diabetes drug, with the FDA asking for additional information on the cardiovascular safety of the treatment. Despite the long approval process, the US has now joined more than 60 other countries which have allowed the drug to enter onto the market.

“The FDA continues to support the development of new drug therapies for diabetes management,” said Dr. Mary Thanh Hai Parks, deputy director, Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Adlyxin will add to the available treatment options to control blood sugar levels for those with type 2.”

Sanofi had originally planned to submit their application to the FDA in 2013, however their plans were put on hold when the agency asked for additional safety studies to be performed. In September of 2015, the company was finally ready to resubmit to the FDA after a 6,000-patient clinical trial cleared up any cardiovascular concerns. Since the drug has been widely-approved in countries across the EU, Sanofi took advantage of the two-year delay by collecting real-world dosing information for the injectable.



“The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose (HbA1c) targets,” said Peter Guenter, Executive Vice President, Head, Global Diabetes & Cardiovascular Business Unit, Sanofi. “We are pleased with this approval, as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled.”

The new diabetes drug is now a direct competitor to Novo Nordisk's Victoza (liraglutide) and Lilly's Trulicity (dulaglutide). Adlyxin is designed to reduce blood sugar levels and increase glucose-dependent insulin secretion by the pancreas.

Victoza pulled in $2.64 billion in sales in 2015, representing an 18 percent increase over the previous year. Sanofi’s Adlyxin is to be used in conjunction with diet and exercise to treat type 2 diabetes.


Keywords: Diabetes, FDA, Drug Approval


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.